This content is only available in Spanish.
Carlos H. Mora-Cevallos 1 , Valeria González-Sacoto 2
, Carmen Ambroj-Navarro 1
, Beatriz Mateo-Hernández 3
, Benjamín Blasco-Beltrán 1
1 Servicio de Urología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España; 2 Servicio de Endocrinología, Hospital de Barbastro, Huesca, España; 3 Servicio de Enfermería en Urología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España
*Correspondence: Carlos H. Mora-Cevallos. Email: carlos_mc12@msn.com
Objective: To evaluate the efficacy and safety of intravesical botulinum toxin type A (BoNT-A) injections in an outpatient setting under local anesthesia in patients with refractory overactive bladder (OAB).
Method: Retrospective observational study on 52 patients with refractory OAB, both idiopathic and neurogenic. Patients with idiopathic OAB received 100 units of BoNT-A, while those with neurogenic OAB were administered 200 units. Pain was assessed using the visual analog scale (VAS), and symptoms were evaluated with the ICIQ-SF questionnaire. Follow-ups were conducted at 1, 6, and 9 months.
Results: At 30 days, 57.7% of patients demonstrated clinical improvement. At 6 months, 48.1% maintained the improvement, while 42.3% sustained it at 9 months. The mean ICIQ-SF score significantly decreased from 18 to 7.25 points (p < 0.001). During the procedure, 90% of patients reported pain levels < 2 on the VAS. The most common complication was hematuria, observed in 34.6% of cases.
Conclusions: Intravesical BoNT-A injections under local anesthesia represent a safe and effective option for the treatment of refractory OAB, providing positive clinical outcomes and high patient satisfaction.
This content is only available in Spanish.
Mallorca, 310
08037 Barcelona (España)
Arquímedes, 190 – Colonia Polanco
Delegación Miguel Hidalgo
11560 Ciudad de México (México)
This journal adheres to the principles established by the Committee on Publication Ethics
The editorial process consists of 6 stages:
1. Reception of the manuscript (indeterminate, depending on whether the author meets the requirements): its objective is to verify that the manuscript complies with the specifications of these instructions for authors and that the submitted documentation is complete.
2. Initial editorial review (maximum 5 business days): its objective is to corroborate the relevance, timeliness, originality, and scientific contribution of the manuscript, as well as the methodological and statistical soundness of the study. At this time, it will be submitted to an electronic plagiarism detection system. Derived from this, a rejected opinion may be obtained, or it will be sent for review by peer researchers.
3. Review by peer researchers (maximum 30 business days): the opinion of at least two experts in the area in question will be obtained, who will evaluate the technical and methodological aspects of the investigation.
4. Editorial review (maximum 7 business days): its objective is to make a decision based on the opinion of peer reviewers. The opinion can be rejected, major changes, minor changes or accepted. In the case of major or minor changes, it will be submitted again for evaluation by the initial peer reviewers.
5. Final edition (6 weeks): its objective is the technical and linguistic edition (and translation), layout of galleys, DOI assignment, and correction by the author.
6. Advanced publication: All manuscripts will be published ahead of print on the journal’s website as soon as they complete the editing process, until they are incorporated into a final issue of the journal.